Evotec and Merck KGaA to collaborate on neurological disease target

Tuesday, 23. November 2010 07:26
Evotec AG /
Evotec and Merck KGaA to collaborate on neurological disease target
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.

Hamburg, Germany - 23 November 2010: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that it has signed within the "NEU²-Consortium"
framework and partially funded by the Federal Ministry of Education and Research
(Bundesministerium fuer Bildung und Forschung - BMBF), an agreement with Merck
KGaA, Darmstadt, Germany, to develop pre-clinical candidates for an undisclosed
neurological disease. Evotec will provide drug discovery expertise covering in
vitro biology, medicinal chemistry and in vitro and in vivo pharmacology.

As part of the collaboration, Evotec will apply their integrated drug discovery
expertise and technologies to identify interesting small molecules for the
selected target. The molecules will be further optimised and progressed through
lead optimization to a pre-clinical candidate.

Dr Mario Polywka, COO of Evotec commented: "We are proud to be part of the NEU²
consortium and we are extremely pleased that Merck KGaA selected Evotec to
collaborate on this interesting Drug Discovery Program which is a further
recognition of our CNS disease expertise."

Contact: Dr Werner Lanthaler, Chief Executive Officer,
Evotec AG, Tel.: +49.(0)40.56081-242, werner.lanthaler@evotec.com

Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. Such forward-looking statements include, but are not limited to,
statements about our expected 2010 financial results and financial growth in
2011, our anticipated financing needs, our ability to deliver on our liquidity
guidance, our belief that we are on course to sustainable profitability latest
in 2012, our expectations and assumptions concerning regulatory, clinical and
business strategies, the progress of our clinical development programmes and
timing of the commencement and results of our clinical trials, strategic
collaborations and management's plans, objectives and strategies. These
statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and uncertainties include,
among other things: risks that product candidates may fail in the clinic or may
not be successfully marketed or manufactured; the risk that we will not achieve
the anticipated benefits of our collaborations, partnerships and acquisitions in
the timeframes expected, or at all; risks relating to our ability to advance the
development of product candidates currently in the pipeline or in clinical
trials; our inability to further identify, develop and achieve commercial
success for new products and technologies; the risk that competing products may
be more successful; our inability to interest potential partners in our
technologies and products; our inability to achieve commercial success for our
products and technologies; our inability to protect our intellectual property
and the cost of enforcing or defending our intellectual property rights; our
failure to comply with regulations relating to our products and product
candidates, including FDA requirements; the risk that the FDA may interpret the
results of our studies differently than we have; the risk that clinical trials
may not result in marketable products; the risk that we may be unable to
successfully secure regulatory approval of and market our drug candidates; and
risks of new, changing and competitive technologies and regulations in the U.S.
and internationally.

The list of risks above is not exhaustive. Our most recent Annual Report on Form
20-F, filed with the Securities and Exchange Commission, and other documents
filed with, or furnished to the Securities and Exchange Commission, contain
additional factors that could impact our businesses and financial performance.
We expressly disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on which any
such statement is based.



[HUG#1464445]



--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


Pdf of Press Release:
http://hugin.info/131215/R/1464445/402900.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE
Related Links: Evotec SE
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.